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Background: Recent studies have shown the presence of vascular endothelial growth factor (VEGF)-
dependent splanchnic angiogenesis in experimental models of portal hypertension, and the role of such
neovascularisation on the development of both portosystemic collaterals and hyperdynamic splanchnic
circulation. However, the mechanisms modulating angiogenesis in portal hypertension are unknown.
Experimental evidence indicates that NAD(P)H oxidase is required for VEGF-induced angiogenesis.
Interestingly, we have recently shown that splanchnic NAD(P)H oxidase activity is significantly increased in
portal hypertensive rats. Therefore, it could be possible that activated NAD(P)H oxidases modulate
angiogenesis in portal hypertension.
Aim: To determine the effects of chronic NAD(P)H oxidase inhibition on angiogenesis and splanchnic
haemodynamics in portal hypertensive rats.
Methods: Partial portal vein-ligated and sham-operated rats were treated with the NAD(P)H oxidase inhibitor
apocynin, or with vehicle for 5 days. Then, the expression of angiogenesis markers (western blotting), the
formation of portosystemic collaterals (radioactive microspheres) and the production of superoxide anion
(lucigenin-enhanced chemiluminescence) were determined. Mean arterial pressure, portal pressure, and
superior mesenteric arterial blood flow and resistance were also measured.
Results: In portal hypertensive rats, NAD(P)H oxidase blockade significantly decreased portosystemic
collateral formation, and superior mesenteric arterial flow. It also reduced the splanchnic expression of VEGF,
VEGF receptor-2 and CD31, and attenuated the increased production of superoxide, compared with vehicle.
Conclusions: NAD(P)H oxidase plays an important role in experimental portal hypertension, modulating
splanchnic angiogenesis, the formation of portosystemic collaterals and the development of splanchnic
hyperdynamic circulation. These results suggest that NAD(P)H oxidase may represent a new target in the
treatment of portal hypertension.
P
ortal hypertension is a frequent and severe complication of
chronic liver diseases.1 2 It is characterised by a pathologi-
cal increase in portal venous pressure through an increase
hepatic resistance to portal blood flow, and by the subsequent
development of an extensive network of portosystemic collat-
eral blood vessels. Even though these vessels aim to lower
portal pressure, portal hypertension is maintained by an
increased blood flow into the portal system, which thus
becomes hyperdynamic.1 2
Recent studies from our laboratory (Hepatic Hemodynamic
Laboratory, Liver Unit, Hospital Clinic, Institut dInvestigacions,
Biomediques August Pi i Sunyer, Barcelona, Spain) on
experimental models of portal hypertension suggest that the
development of portosystemic collateral vessels is, at least in
part, an active angiogenic process modulated by vascular
endothelial growth factor (VEGF).3 4 These studies further
showed that the increased splanchnic blood flow characteristic
of portal hypertension is not only due to splanchnic vasodilata-
tion, but it is also mediated through an increased VEGF-
dependent splanchnic vascularity.4
The precise mechanisms by which angiogenesis-associated
responses are modulated in portal hypertension remain to be
defined. Experimental evidence indicates that NAD(P)H oxi-
dases, a major source of reactive oxygen species (ROS) in the
vasculature,5 6 are required for VEGF-dependent angiogenesis.7–11
Interestingly, we have recently shown that NAD(P)H oxidase
activity is significantly increased in splanchnic organs from portal
hypertensive rats, as compared with sham-operated animals.12
Previous studies have also suggested that the portal hypertensive
syndrome is associated with increased oxidative stress.13 14
Therefore, it could be possible that activated NAD(P)H oxidases
play a role in angiogenesis-associated responses in portal
hypertension. To test this hypothesis, we determined the effects
of chronic inhibition of NAD(P)H oxidase on the splanchnic
neovascularisation, the extent of portosystemic collateral vessels,
and the development of hyperdynamic splanchnic circulation in
portal hypertensive rats and in sham-operated control animals.
MATERIALS AND METHODS
Animals and experimental groups
Experimental procedures were approved by the ‘‘Laboratory
Animal Care and Use Committee’’ of the Institut
dInvestigacions, Biomediques August Pi i Sunyer, at the
University of Barcelona, and performed according to the criteria
outlined in the ‘‘Guide for the Care and Use of Laboratory
Animals’’ published by the US National Institutes of Health
(NIH publication 86–23, revised 1985).
Male Sprague-Dawley rats (350–400 g body weight; Charles
River, Cambridge, Massachusetts, USA) were used in this
Abbreviations: ROS, reactive oxygen species; TBS, Tris-buffered saline;
VEGF, vascular endothelial growth factor; VEGFR-2, VEGF receptor-2
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study. Portal hypertension was induced by partial portal vein
ligation, as described previously.15 Briefly, under ketamine and
xylacine anaesthesia (80 and 12 mg/kg body weight, respec-
tively, intramuscularly), the portal vein was isolated, and a
stenosis was created by a single ligature of 3–0 silk placed
around both the portal vein and a 20 gauge blunt-tipped
needle. The needle was then removed, leaving a calibrated
constriction of the portal vein. In sham-operated control
animals, the portal vein was isolated and similarly manipu-
lated, but not ligated. Studies were performed 5 days after the
initial surgery.
Rats received daily intraperitoneal injections of the NAD(P)H
oxidase inhibitor apocynin (30 mg/kg/day; partial portal vein
ligated rats: n = 10; sham-operated rats: n = 5; Sigma
Chemical, St Louis, Missouri, USA), or its vehicle (0.3 ml
dimethyl sulfoxide; partial portal vein ligated rats: n = 10;
sham-operated rats: n = 5; Sigma), starting immediately after
surgery, and then every day for a total of 5 days. The dose of
apocynin used has been previously shown to be effective in
inhibiting NAD(P)H oxidase activity.16
Haemodynamic studies
Under anaesthesia with ketamine and xylacine, a tracheotomy
was performed and a polyethylene PE-240 tubing was inserted
into the trachea to ensure a patent airway. PE-50 catheters were
introduced into the femoral artery, to record arterial pressure
(mm Hg), and into the portal vein through an ileocolic vein, to
measure portal pressure (mm Hg). Then, the superior mesen-
teric artery was carefully dissected free from the connective
tissue, and a non-constrictive perivascular transit-time ultra-
sonic flowprobe (1PR, 1-mm diameter; Transonic Systems,
Ithaca, New York, USA) was placed around this vessel close to
its aortic origin. The flow probe was connected to a flowmeter,
to measure the superior mesenteric arterial blood flow (ml/min/
100 g).17 Resistance in the superior mesenteric artery (mm Hg/
ml/min/100 g) was calculated as: (mean arterial pressure–
portal pressure)/superior mesenteric arterial blood flow. Blood
pressures and flows were registered on a multichannel
computer-based recorder (PowerLab; ADInstruments,
Colorado Springs, Colorado, USA). The external zero reference
point was placed at the midportion of the animal. Studies were
performed after a 30-min stabilisation period.
Determination of the extent of portosystemic collateral
formation
The extent of portosystemic collateral vessels was quantified
using 51Cr-labelled radioactive microspheres (Perkin-Elmer;
Boston, Massachusetts, USA) injected into the portal vein via a
distal ileocolic vein.18 The radioactivity in the liver and lungs
was determined in a c-scintillation counter. This allows
quantification of the degree of collateral formation in a 0–
100% scale, by the equation: collateralisation (%) = [lung
radioactivity/(lung radioactivity + liver radioactivity)] 6 100.
Approximately 30 000 51Cr-labelled microspheres (diameter 15
(3) mm; specific activity 41 mCi/g) were injected into the distal
ileocolic vein of each animal.
Quantification of NAD(P)H oxidase-dependent
superoxide production
NAD(P)H oxidase-dependent superoxide anion production was
assessed in the rat mesentery by lucigenin-enhanced chemilu-
minescence.19 Briefly, tissues were excised, immediately snap-
frozen in liquid nitrogen and stored at 280 C˚ for analysis.
Tissues were minced thoroughly with mortar under liquid
nitrogen. A 10% homogenate was prepared by homogenising
the obtained powder in 1 ml of Krebs-HEPES buffer, contain-
ing 0.01 mM EDTA and 0.01 mM ethylene glycol tetraacetic
acid (pH 7.4; Sigma), by using a glass-to-glass homogeniser.
The homogenate was centrifuged at 1000 g for 10 min, to
remove unbroken cells and debris. Protein quantification was
performed by the Lowry method, and the final concentration
adjusted to 10 mg/ml. For the chemiluminescence assay, 100 ml
aliquots were added to 400 ml of a Krebs-HEPES assay solution
containing lucigenin (5 mM; Sigma) as the electron acceptor.
After equilibration and background counts, NAD(P)H (0.1 mM;
Sigma) was added as the substrate, and the luminescence
counts (relative light units) were monitored continuously over
a 3-min period in a luminometer, at 37 C˚. Then, superoxide
dismutase (400 U/ml; Sigma) was added and counts were
measured again for 3 min.
Western blot analysis
Protein expressions of VEGF, VEGF receptor-2 (VEGFR-2) and
CD31 in the rat intestine were determined by western blotting,
as described previously.3 4 In brief, tissues were homogenised in
ice-cold lysis buffer containing 50 mM Tris-HCl (pH 7.4),
0.1 mM ethylene glycol tetraacetic acid, 0.1 mM EDTA, 2 mM
leupeptin, 1 mM phenylmethylsulfonyl fluoride, 1% Nonidet
P40, 0.1% sodium dodecyl sulphate and 0.1% deoxycholate
(Sigma). The resultant lysates were centrifuged at 10 000 g for
30 min at 4 C˚. The supernatants were collected and total
protein was quantified using a colorimetric assay (Bio-Rad
Laboratories; Hercules, California, USA). Samples (100 mg
protein) were mixed with double-strength sample buffer
(250 mM Tris-HCl, 4% sodium dodecyl sulphate, 10% glycerol,
2% b-mercaptoethanol and 0.006% bromophenol blue
(pH 6.8)), boiled for 5 min and subjected to 7.5% sodium
dodecyl sulphate-polyacrylamide gel electrophoresis. Proteins
were transferred to nitrocellulose membranes (Bio-Rad), and
stained with Ponceau S solution (Sigma), to check for equal
loading of protein in each lane. Membranes were blocked in
Tris-buffered saline (TBS) with 0.05% Tween 20 (TBS-T buffer)
containing 10% (wt/vol) non-fat dry milk. The membranes were
then incubated, overnight at 4 C˚, with polyclonal monospecific
antibodies against VEGF, VEGFR-2, and CD31 (1:200 dilution
in TBS-T with 5% milk; Santa Cruz Biotechnology, Santa Cruz,
California, USA). Blots were subsequently washed in TBS-T and
incubated with horseradish peroxidase-conjugated antibody
against rabbit IgG (1:10 000 dilution in TBS-T with 5% milk;
Stressgen, Sidney, Canada) for 30 min at room temperature.
Immunoreactive bands were detected using the enhanced
chemiluminescence western blotting system (Santa Cruz).
Molecular weight was calculated with prestained standards
(Bio-Rad). The western blot analysis was repeated to confirm
reproducibility using the samples collected from three indivi-
dual rats of each experimental group.
Statistical analysis
Results are expressed as mean (SEM). Data were normally
distributed, and, therefore, we used parametric statistical
procedures (Student’s test for unpaired data, and 2-way
analysis of variance followed by the Tukey-Kramer test for
multiple comparisons). Differences were considered significant
at p,0.05.
RESULTS
All animals had a similar body weight at the time of the studies.
Treatments were well tolerated and no side effects were
observed during the treatment period.
Effects of chronic NAD(P)H oxidase inhibition on the
expression of angiogenesis markers
We determined the effects of chronic NAD(P)H oxidase
inhibition on intestinal VEGF, VEGFR-2 and CD31 protein
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expression in portal hypertensive rats, and in sham-operated
control animals. NAD(P)H oxidase blockade significantly
reduced the expression of the angiogenic factor VEGF and its
receptor VEGFR-2 in rats with portal hypertension, as
compared with vehicle-treated portal hypertensive rats (fig 1).
In addition, the expression of CD31, which is widely used as a
marker of neovascularisation,20 was also significantly lower in
portal hypertensive rats treated with the NAD(P)H oxidase
inhibitor than in those receiving vehicle (fig 1). In sham-
operated rats, blockade of NAD(P)H oxidase had no significant
effects on the protein expression of angiogenesis markers (data
not shown).
Effects of chronic NAD(P)H oxidase inhibition on the
formation of portosystemic collateral vessels
As expected, vehicle-treated portal hypertensive rats had a
higher degree of collateral vessel formation than vehicle-treated
sham-operated animals (55.1% (7.0%) vs 0.08% (0.01%),
p,0.001). Interestingly, chronic NAD(P)H oxidase blockade
caused a marked and significant inhibition (by 55%) of the
formation of portosystemic collateral vessels in portal hyper-
tensive rats, compared with the vehicle-treated group (fig 2A).
In sham-operated control animals, blockade of NAD(P)H
oxidase had no significant effects on the formation of
portosystemic collaterals (data not shown). These results were
also confirmed in additional studies performed at a later time
point during the evolution of portal hypertension. Thus, the
degree of collateral formation was significantly lower in portal
hypertensive rats receiving the NAD(P)H oxidase inhibitor for
8 days (26.06% (9.45%); n = 7) than in vehicle-treated portal
hypertensive rats (83.38% (6.82%); n = 6, p = 0.00075).
Effects of chronic NAD(P)H oxidase inhibition on mean
arterial pressure and splanchnic haemodynamics
Portal hypertensive rats had significantly higher portal pressure
and superior mesenteric arterial blood flow, and significantly
lower superior mesenteric arterial resistance than sham-
operated rats (fig 3).
In portal hypertensive rats, NAD(P)H oxidase inhibition
caused a significant decrease in superior mesenteric arterial
blood flow, increasing the superior mesenteric arterial resis-
tance, in comparison with portal hypertensive animals receiv-
ing vehicle (fig 3). Portal pressure decreased after NAD(P)H
oxidase blockade in portal hypertensive rats, but the difference
did not reach statistical significance (p = 0.081 vs vehicle-
treated portal hypertensive rats). Mean arterial pressure was
not significantly modified after inhibition of NAD(P)H oxidase
in portal hypertensive rats (fig 3).
In sham-operated rats, chronic NAD(P)H oxidase blockade
had no significant haemodynamic effects (fig 3).
Effects of chronic NAD(P)H oxidase inhibition on
superoxide anion production
To show the efficacy of the apocynin treatment in inhibiting
NAD(P)H oxidase activity in portal hypertensive rats, we
determined mesenteric superoxide anion levels using the
lucigenin-enhanced chemiluminescence method. Superoxide
levels were significantly lower in apocynin-treated portal
hypertensive rats than in those receiving vehicle (fig 2B). In
all assays, NAD(P)H did not evoke lucigenin chemilumines-
cence in the absence of homogenate. In addition, to ensure that
the chemiluminescence signal obtained in the presence of
NAD(P)H was attributable to superoxide, we examined the
effects of a selective superoxide scavenger. NAD(P)H-depen-
dent chemiluminescence was completely abolished by super-
oxide dismutase, confirming the specificity of the assay.
DISCUSSION
This study shows that chronic NAD(P)H oxidase inhibition
markedly and significantly attenuates the formation of
portosystemic collateral vessels, and the development of
hyperdynamic splanchnic circulation in portal hypertensive
rats. To our knowledge, this study is the first demonstration
that NAD(P)H oxidase plays a pathophysiological role in
experimental portal hypertension. These findings also suggest
that inhibition of NAD(P)H oxidase activity might have
therapeutic potential in the treatment of portal hypertension.
The effects of NAD(P)H oxidase blockade attenuating the
extent of collateralisation and the splanchnic hyperaemia of
portal hypertensive rats were most probably mediated through
inhibition of VEGF-induced angiogenesis. This is based on the
following considerations: first, in recent studies performed on
experimental models of portal hypertension, we have shown
that these animals have a marked and progressive over-
expression of VEGF, VEGFR-2 and CD31 in splanchnic
tissues.3 4 Inhibition of such splanchnic neovascularisation,
using either a monoclonal antibody against VEGFR-2, or a
specific inhibitor of VEGFR-2, resulted in a significant decrease
in the formation of portosystemic collateral vessels, as well as in
an attenuation of the hyperdynamic splanchnic circulation.3 4
Figure 1 Effects of chronic NAD(P)H oxidase inhibition on vascular endothelial growth (VEGF), VEGF receptor-2 (VEGFR-2), and CD31 protein expression
in the intestine of portal hypertensive rats. (A) Representative western blots for VEGF, VEGFR-2, and CD31 in portal hypertensive rats treated with the
NAD(P)H oxidase inhibitor apocynin or with vehicle. (B) Densitometric quantification of VEGF, VEGFR-2, and CD31 protein expression (expressed as % of
the vehicle-treated portal hypertensive group, as control; mean (SEM) of three different experiments). *p,0.05 vs vehicle-treated portal hypertensive rats.
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These results suggest that the formation of collaterals in portal
hypertension is not only due to the opening of pre-existing
blood vessels because of the increase in portal venous pressure,
as it has been traditionally thought,1 but it is also mediated by a
VEGF-dependent angiogenic process. In addition, our recent
data indicate that an increased splanchnic neovascularisation
significantly contributes to the splanchnic hyperaemia asso-
ciated with portal hypertension, on top of the well-established
role of splanchnic vasodilatation.1 Second, our results show that
chronic NAD(P)H oxidase inhibition significantly decreased the
protein expression of the angiogenic factor VEGF and its
receptor VEGFR-2 in splanchnic organs from portal hyperten-
sive rats. The expression of CD31, as an index of vascular
density,20 was also significantly reduced after NAD(P)H oxidase
blockade in rats with portal hypertension. In addition, the
excessive splanchnic ROS production, observed in splanchnic
tissues from portal hypertensive rats,12 was also significantly
attenuated after treatment with the NAD(P)H oxidase inhibi-
tor, as compared with the vehicle-treated group. Taken
together, these results suggest that NAD(P)H oxidase-derived
ROS are critically important in VEGF-induced angiogenesis in
portal hypertensive rats. At this point, we cannot rule out a
possible role of VEGF-independent mechanisms mediating the
effects of NAD(P)H oxidase blockade in portal hypertensive
rats.
The underlying molecular mechanisms by which activation
of NAD(P)H oxidase stimulates angiogenesis are incompletely
understood.7–11 In this regard, it has been shown that ROS
produced by NAD(P)H oxidases can activate multiple signalling
pathways, such as mitogen-activated protein kinases, tyrosine
kinases and transcription factors,21 which have been implicated
in VEGF-induced neovascularisation.22–24 Accumulating evi-
dence suggests that ROS can also modulate angiogenesis via
induction of VEGF and VEGFR-2 expression.25 26 Interestingly,
our results show that NAD(P)H oxidase blockade significantly
decreases VEGF and VEGFR-2 protein expressions in portal
hypertensive rats. Therefore, two potential mechanisms by
which NAD(P)H oxidase stimulates angiogenesis in portal
hypertensive rats could be by increasing the expression of VEGF
and/or that of its receptor. It should be noted that, as VEGFR-2
is exclusively expressed on vascular endothelial cells,24 its down
regulation may also reflect the overall decrease in splanchnic
vascularity (ie, CD31 expression) observed in portal hyperten-
sive rats after NAD(P)H oxidase inhibition.
Recently, we have also shown that the increased baseline
oxidative stress observed in portal hypertensive rats is, at least
in part, responsible for the upregulation of the enzyme heme
oxygenase-1 in this experimental model.12 27 28 Thus, when
oxidative stress was reduced in portal hypertensive rats by
Figure 2 Effects of chronic NAD(P)H oxidase inhibition (A) on the
formation of portosystemic collateral vessels, and (B) on the mesenteric
production of superoxide anion in portal hypertensive rats. Results are
shown as mean (SEM). *p,0.05 vs vehicle-treated portal hypertensive rats.
Figure 3 Effects of chronic NAD(P)H oxidase inhibition on mean arterial pressure and splanchnic haemodynamics in portal hypertensive (PH) and sham-
operated (SO) rats. Results are shown as mean (SEM). * p,0.05 vs apocynin-treated sham-operated rats;  p,0.05 vs vehicle-treated sham-operated rats;
` p,0.05 vs vehicle-treated portal hypertensive rats.
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chronic inhibition of NAD(P)H oxidase, heme oxygenase-1
protein expression was also significantly down regulated.12 In
addition, another salient finding of our previous study is that
chronic heme oxygenase inhibition markedly and significantly
decreases (by 74%) VEGF protein expression in the mesentery
of portal hypertensive rats, suggesting that heme oxygenase
enzymatic activity is an important stimulus for VEGF produc-
tion in portal hypertension. Taken together, these results
suggest that oxidative stress modulates angiogenesis in portal
hypertension directly by activating the intracellular VEGF
signalling pathway, and indirectly by stimulating the induction
of heme oxygenase-1, which, in turn, increases the expression
of VEGF.
Multiple physiological agents, which may be increased
during portal hypertension, including cytokines, shear stress
and ischaemia, have been shown to activate NAD(P)H
oxidase.5 6 29 Interestingly, the production of ROS has also been
shown to be triggered secondarily to stimulation by growth
factors, such as VEGF, indicating that NAD(P)H oxidase may
also act downstream from VEGF signalling.11 Whether one or
more of these factors stimulate NAD(P)H oxidases in portal
hypertensive rats requires further investigation. In addition to
portal hypertension, NAD(P)H oxidases contribute to excessive
ROS production in other diseases such as hypertension,30 31
atherosclerosis,32 diabetic vascular diseases,33 cardiac hypertro-
phy and heart failure.34 35
In summary, this study provides compelling evidence that
NAD(P)H oxidase plays an important role modulating angio-
genesis-dependent processes (ie, formation of portosystemic
collaterals, increased splanchnic vascularity and development
of hyperdynamic splanchnic circulation) in portal hypertensive
rats. These findings suggest that NAD(P)H oxidase may serve
as a novel therapeutic target for portal hypertension.
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